How Big of an Opportunity Do Pfizer and BioNTech Have in Vaccinating Younger Kids?

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently reported positive data from a late-stage study of their COVID-19 vaccine in children ages 5 to 11. The companies plan to soon file for Emergency Use Authorization in this age group. In this Motley Fool Live video recorded on Sept. 22, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how big of an opportunity Pfizer and BioNTech have in vaccinating younger kids.

Continue reading

Source Fool.com